Optimized for each specific cell type; maximize results
No Issues
Therapy Supply Chain – DMSO limited
A typical cell therapy supply chain where the effectiveness of the therapy can depend on the viability of the original collected human cells
Step 1
Human cells collected from the patient or a donor (e.g., t-cells as part of a CAR-T)
Step 2
Because human cells cannot survive long outside the body without preservation, these delicate collected cells are preserved via cryopreservation for transport to a therapy manufacturing facility. With the toxic effects of DMSO, often only 50% of the original cell viability and functionality remains after the required freeze and thaw.
Step 3
The thawed cells are utilized for manufacture of a needed therapy. Again, cryopreservation is needed for the transport of the therapy containing the cells to the point of patient care.
Step 4
The therapy containing the cells is thawed in preparation for patient infusion. Again, the functionality and viability of the cells in the therapy are reduced due to the toxic nature of DMSO.
Step 5
The therapy that was preserved in DMSO, is infused into the patient, often resulting in patient safety issues ranging from nausea to sometime cardia arrest.
Step 1
Human cells collected from the patient or a donor (e.g., t-cells as part of a CAR-T)
Step 2
Because human cells cannot survive long outside the body without preservation, these delicate collected cells are preserved via cryopreservation for transport to a therapy manufacturing facility. With the toxic effects of DMSO, often only 50% of the original cell viability and functionality remains after the required freeze and thaw.
Step 3
The thawed cells are utilized for manufacture of a needed therapy. Again, cryopreservation is needed for the transport of the therapy containing the cells to the point of patient care.
Step 4
The therapy containing the cells is thawed in preparation for patient infusion. Again, the functionality and viability of the cells in the therapy are reduced due to the toxic nature of DMSO.
Step 5
The therapy that was preserved in DMSO, is infused into the patient, often resulting in patient safety issues ranging from nausea to sometime cardia arrest.
DMSO technology damages cells, causes high cell losses during manufacturing and is harmful to patients.
Dimethylsulfoxide “DMSO”
Organic Industrial solvent
Manufacturing processes often result in cells being exposed to DMSO for extended periods of time
Patient infused with cells containing DMSO frequently have adverse reactions